SCHEMBL25899906

SCHEMBL25899906

O=C1Cc2cc(Cl)ccc2N1CCO

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BMPR1B O00238 2/20 0.47
BMPR1A P36894 2/20 0.47
TGFBR1 P36897 2/20 0.47
ACVRL1 P37023 2/20 0.47
ACVR1 Q04771 2/20 0.47
KMO O15229 1/20 0.46
DRD2 P14416 3/20 0.45
DRD4 P21917 2/20 0.45
HDAC6 Q9UBN7 3/20 0.43
HDAC1 Q13547 2/20 0.43
HDAC8 Q9BY41 2/20 0.43
DRD3 P35462 2/20 0.42
DRD5 P21918 1/20 0.42
CRHR1 P34998 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
KCNK2 O95069 1/20 0.40
MAPT P10636 1/20 0.40
ALOX12 P18054 1/20 0.40
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2951133 0.87 HDAC1 (0.45) KMODRD2DRD4HDAC6HDAC1
SCHEMBL26021803 0.84 BMPR1B (0.48) BMPR1BBMPR1ATGFBR1ACVRL1ACVR1
SCHEMBL31419471 0.81 ATAD2 (0.50) BMPR1BBMPR1ATGFBR1ACVRL1ACVR1
SCHEMBL26621670 0.81 ATAD2 (0.50) BMPR1BBMPR1ATGFBR1ACVRL1ACVR1
SCHEMBL25899986 0.81 BMPR1B (0.50) BMPR1BBMPR1ATGFBR1ACVRL1ACVR1
SCHEMBL8146689 0.81 BMPR1B (0.47) BMPR1BBMPR1ATGFBR1ACVRL1ACVR1
SCHEMBL14368230 0.81 BMPR1B (0.50) BMPR1BBMPR1ATGFBR1ACVRL1ACVR1
SCHEMBL11526516 0.81 BRD4 (0.55) BMPR1BBMPR1ATGFBR1ACVRL1ACVR1
SCHEMBL26021791 0.81 BMPR1B (0.51) BMPR1BBMPR1ATGFBR1ACVRL1ACVR1
SCHEMBL2009991 0.80 PTGDR2 (0.49) KMOHDAC6HDAC1HDAC8KCNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2023-08-24 US disclosed
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2023-08-24 US disclosed
WO-2023141432-A2 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS, INC. (US) 2023-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, LDLR BMPR1B 2037/4885BMPR1A 1194/4885TGFBR1 463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.